Hormonal
Sleep disruption (fragmentation/continuity loss) causes increased sympathetic nervous system activity and HPA axis activation, leading to short-term stress responsivity and long-term cardiovascular disease risk.
Prioritize sleep continuity, not just duration. If you wake up frequently, your body experiences a stress response similar to being awake, increasing long-term risks for heart disease and high blood pressure. Focus on strategies to maintain uninterrupted sleep, such as managing environmental factors (light/noise) and addressing underlying sleep disorders like apnea.
Sleep disruption is associated with increased activity of the sympathetic nervous system and hypothalamic–pituitary–adrenal axis... In otherwise healthy adults, short-term consequences of sleep disruption include increased stress responsivity... Long-term consequences of sleep disruption in otherwise healthy individuals include hypertension, dyslipidemia, cardiovascular disease...
Why this rating
Based on a nonsystematic review of 97 references, including prospective cohort studies and meta-analyses showing significant relative risks for hypertension and CVD.
Source
Short- and long-term health consequences of sleep disruption
Goran Medić et al. · Nature and Science of Sleep · 2017
DOI 10.2147/nss.s134864
More from this paper
- Sleep disruption leads to metabolic dysregulation (decreased insulin sensitivity, altered leptin/ghrelin) increasing the risk of obesity, metabolic syndrome, and type 2 diabetes.Good
- Sleep disruption is associated with an increased risk of certain cancers (colorectal, breast, prostate) and all-cause mortality, particularly in men.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →